British Journal of Clinical Pharmacology · 1985 · 105 citations · 24 references
PharmacyPharmacologyPharmacotherapyHypersensitivityPharmacodynamicsPulmonary Function TestingAsthma ManagementAsthma PharmacotherapyBronchodilator TherapyRespiratory PharmacologyAntagonist ActivityAntagonist PotencyInhaled TherapiesPharmacodynamics Of Inhaled DrugsTheophylline Therapy
The airway response to increasing concentrations of inhaled-adenosine and histamine after oral theophylline or matched placebo was studied in nine asthmatic subjects. Changes in airway calibre were followed as sGaw and FEV1 and concentration-response curves constructed. Inhaled adenosine caused concentration-related bronchoconstriction and was four-five times less potent than inhaled histamine. Theophylline, which achieved a mean plasma level of 15.9 and 16.6 micrograms/ml on the histamine and adenosine study days respectively, caused significant increases in FEV1 (17%) and sGaw (41-53%) whereas placebo had no effect. Theophylline also protected the airways against histamine-and adenosine-induced bronchoconstriction. However theophylline had a greater protective effect against adenosine (concentration-ratio 17.4 for FEV1 and 12.8 for sGaw) than against histamine (concentration ratio 5.6 for FEV1 and 5.4 for sGaw (P less than 0.05]. At therapeutic concentrations theophylline is a specific antagonist of the airway effects of adenosine in addition to being a bronchodilator and a functional antagonist.
24
The control of the metabolism and the hormonal role of adenosine.
J R Arch, Eric A. Newsholme · PubMed · 1978 · 415 citations